Bristol-Myers Squibb Company (BMV:BMY)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.40T +50.5% |
| Revenue (ttm) | 901.82B +4.2% |
| Net Income | 166.60B +53.1% |
| EPS | 84.78 +51.9% |
| Shares Out | n/a |
| PE Ratio | 13.56 |
| Forward PE | 9.71 |
| Dividend | 45.15 (3.93%) |
| Ex-Dividend Date | Oct 2, 2026 |
| Volume | 23 |
| Open | 1,150.00 |
| Previous Close | 1,100.00 |
| Day's Range | 1,149.30 - 1,150.00 |
| 52-Week Range | 805.00 - 1,185.00 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About BMV:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
News
Bristol Myers price target lowered to $40 from $41 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Bristol Myers (BMY) to $40 from $41 and keeps an Underweight rating on the shares.
Bristol Myers price target lowered to $60 from $65 at Wells Fargo
Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal Weight rating on the shares. The firm sees…
How Bristol Myers's CEO Challenged the Company's Managers
When Alan and I talked with Chris Boerner recently, a critical aspect of his leadership style was apparent immediately: He confronts issues head on.
Bristol-Myers Squibb Company Earnings Call Transcript: Q3 2026
Q3 revenue rose 7% and growth portfolio sales grew 12%, prompting higher FY 2026 guidance. Pipeline readouts and launches advanced, while the 2027 ELIQUIS LOE remains a significant headwind.
Bristol-Myers Squibb Company Earnings release: Q3 2026
Bristol-Myers Squibb Company released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Bristol-Myers Squibb Company Slides: Q3 2026
Bristol-Myers Squibb Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Bristol-Myers Squibb Company Quarterly report: Q3 2026
Bristol-Myers Squibb Company has published its Q3 2026 quarterly earnings report on October 29, 2026.
Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises
Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Bristol Myers Squibb raised its full-year revenue forecast on Thursday, citing strong sales of its newer medicines, but lowered its 2026 earnings per share projection due to a hefty acquisition-relat...
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2026.
Bristol Myers price target lowered to $78 from $82 at Piper Sandler
Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $78 from $82 and keeps an Overweight rating on the shares. The firm is reviewing the Q3 cycle…
Bristol Myers, SystImmune announce results from Phase 3 study of iza-bren
SystImmune and Bristol Myers (BMY) Squibb announced that SystImmune’s parent company Sichuan Biokin reported positive results from a prespecified interim analysis in the randomized, multicenter Phase ...
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small...
BioNTech, Bristol Myers announces data from Phase 2 ROSETTA Lung-107 trial
BioNTech (BNTX) and Bristol Myers Squibb Company (BMY) announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific imm...
Bristol Myers tells Bloomberg aims to resume paused CAR-T trials in 2027
A Bristol Myers (BMY) spokesperson stated in an email to Bloomberg that the company has identified the cause of an earlier-observed CAR-T safety signal and that the company aims to…
Bristol Myers discloses death of CAR T patient in MS study
Bristol Myers (BMY) disclosed that one patient with highly active relapsing multiple sclerosis experienced a fatal event of septic pneumonia in its Phase 1 trial. Following zola-cel infusion, the pati...
Bristol Myers presents results from Phase 1 Breakfree-2 study
Bristol Myers (BMY) Squibb announced disclosure of interim safety and efficacy results from the multiple sclerosis cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zola...
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
Pathos AI secures $237M in Series E financing
Pathos AI announced the closing of a $237M Series E financing round at a post-money valuation of approximately $3B. The financing was led by Bristol Myers (BMY) Squibb, alongside participation…
Pathos AI enters collaborations with Bristol Myers, Tempus AI
Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease ...
Tempus AI expands collaboration with Bristol Myers
Tempus AI (TEM) announced a multi-year agreement with Bristol Myers Squibb (BMY), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insi...
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology ...
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing...
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (...
Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
Bristol Myers Squibb and partner SystImmune said on Friday their experimental breast cancer treatment slowed disease progression compared to standard chemotherapy in a late-stage study.